Clinical Trial Update: Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update reporting results from a Phase 2/3 study of tucatinib + trastuzumab + ramucirumab + paclitaxel vs paclitaxel + ramucirumab in previously t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Cyramza (ramucirumab)
• HERCEPTIN (trastuzumab)
• Taxol (paclitaxel)
• Tukysa (tucatinib)

Snippet

Sponsor: Seagen Inc. | Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-01-22